Search Within

Dana Elizabeth Rathkopf

Formats
  1. Meeting Abstract (161)
  2. Journal Article (108)
  3. Review (4)
  4. Editorial (3)
  5. Correspondence (1)
Groups
  1. Department of Medicine (277)
  2. Genitourinary Oncology Service (277)
  3. Solid Tumor Oncology Division (277)
  4. Hematologic Malignancies, Division of (70)
  5. GSK Faculty (53)
  6. Department of Pathology and Laboratory Medicine (43)

More Groups

People
  1. Howard Scher (133)
  2. Michael Morris (79)
  3. Susan Slovin (59)
  4. Daniel Danila (45)
  5. Karen Autio (34)
  6. Wassim Abida (31)

More People

Years
  1. 2025 (13)
  2. 2024 (20)
  3. 2023 (19)
  4. 2022 (16)
  5. 2021 (18)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (122)
  2. Annals of Oncology (27)
  3. European Urology (17)
  4. Clinical Cancer Research (13)
  5. Cancer Research (9)
  6. European Journal of Cancer (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (125)
  2. Oxford University Press (28)
  3. American Association for Cancer Research (26)
  4. Elsevier Science, Inc. (25)
  5. Elsevier Inc. (16)
  6. Nature Publishing Group (9)

More Publishers

Results (277)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study
    Meeting Abstract

    Fleming, M. T.; Rathkopf, D. E.; Gibbons, J.; Peterson, A. C.; Hannah, A.; Forer, D.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302
    Meeting Abstract

    Ryan, C. J.; Londhe, A.; Molina, A.; Smith, M. R.; De Bono, J. S.; Mulders, P.; Rathkopf, D. E.; Saad, F.; Logothetis, C.; Fizazi, K.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P)
    Meeting Abstract

    Saad, F.; Fizazi, K.; Smith, M. R.; Griffin, T. W.; Londhe, A.; Rathkopf, D. E.; Molina, A.; Ryan, C. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)
    Meeting Abstract

    Rathkopf, D. E.; Smith, M. R.; De Bono, J. S.; Logothetis, C.; Shore, N.; De Souza, P. L.; Fizazi, K.; Mulders, P.; Mainwaring, P. N.; Hainsworth, J. D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib
    Meeting Abstract

    Fox, J. J.; Haupt, E. C.; Humm, J.; Autio, K. A.; Rathkopf, D. E.; Vargas, H. A.; Schöder, H.; Hricak, H.; Larson, S. M.; Scher, H. I.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer
    Meeting Abstract

    Fleming, M. T.; Rathkopf, D. E.; Gibbons, J.; Peterson, A. C.; Hannah, A.; Forer, D.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel
    Meeting Abstract

    Chi, K. N.; San Kheoh, T.; Ryan, C. J.; Molina, A.; Bellmunt, J.; Vogelzang, N. J.; Rathkopf, D. E.; Fizazi, K.; Kantoff, P. W.; Li, J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Attard, G.; De Bono, J. S.; Li, W.; Molina, A.; Griffin, T. W.; Kheoh, T. S.; Ricci, D. S.; Zelinsky, K.; Rathkopf, D. E.; Scher, H. I.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Efficacy and safety of abiraterone acetate (AA) in elderly (75 years) chemo-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Smith, M. R.; Rathkopf, D.; Mulders, P.; Carles, J.; Van Poppel, H.; Li, J.; Kheoh, T.; Griffin, T.; Molina, A.; Ryan, C.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save